

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

February 7, 2019

9:30am- 11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR .DAPHNE B. BERNARD, PHARM.D. R.PH CHAIRPERSON	
	MR. JAMES APPLEBY, R.PH VICE CHAIR	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	MR. ALAN FRIEDMAN, R.PH	
	DR. TAMARA MCCANTS, PHARM.D. R.PH	
	CHIKITA SANDERS, CONSUMER BOARD MEMBER	
STAFF:	SHAUNA WHITE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, HEALTH LICENSING SPECIALIST	
	LAWRENCE HOLLAND, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
0207-O-01	<u>Approval of the Open Session Meeting Minutes</u> December 6, 2018 January 3, 2019	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<u>Licensing Report</u> Statistics New Licensing Renewal Portal Pharmacists and Pharmacy Technician Renewal Information Cardiopulmonary Resuscitation (CPR) Training Policy Statement Prescription Monitoring Program Update Opioid Strategic Plan Clinical Lab Practitioner Advisory Committee Updates Naloxone Update	
<u>Assistant General Counsel Report</u>	None	Carla Williams
<u>Subcommittee Report</u>		
	<u>Legislative and Regulatory</u>	Alan Friedman
0207-O-02	Defending Access to Women’s Health Care Services Amendment Act of 2017	
0207-O-03	<u>Communications Subcommittee Report</u>	Dr. Daphne Bernard
0207-O-04	<u>Summary of NABP E-News Intern Presentation</u>	

<p>NABP E-Newsletter</p>	<p><u>January 23, 2019</u></p> <p>NABP 2019 <i>Survey of Pharmacy Law</i> Now Available</p> <p>Synthetic Opioids Contribute to Increase in Drug Overdose Deaths in US, CDC Reports</p> <p>FDA Creates Model Drug Facts Label to Support Development of Over-the-Counter Naloxone</p> <p>Lupin Pharmaceuticals Recalls 42 Lots of Ceftriaxone for Injection USP Due to Particulate Matter</p> <p>FDA Warns of Hidden Drug Ingredients in Slimina and The Silver Bullet; Warns Consumers Not to Purchase</p> <p><u>January 9, 2019</u></p> <p>HHS Releases Guidance on Naloxone, Recommends Co-Prescribing to Reduce Overdose Deaths</p> <p>CPPA Awards Telehealth Accreditation to SinfoníaRx, Inc, Austin, TX and Gainesville, FL Locations</p> <p>FTC Sues Sellers of Nobetes, a Pill Claiming to Treat Diabetes</p> <p>Aurobindo Pharma USA Issues Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP, and Valsartan Tablets USP</p>	
<p><u>Matters for Board Consideration</u></p>		
<p>0207-O-05</p>	<p>Collaborative Practice Agreements – 22-B DCMR Chapter 10006 requires the Board of Pharmacy and Medicine to approve Collaborative Practice Agreements if a physician and a pharmacist intend to manage or treat a condition or disease state for which there is not a protocol that is generally accepted as the clinical standard of care, the physician and pharmacist shall apply for approval. The Boards shall receive and review the proposed treatment protocol and jointly approve or disapprove.</p> <p>Application and approval are not needed for treatment of conditions for which there is a generally accepted clinical standard of care, but for which the physician wants to increase the monitoring and oversight of the condition over what the protocol recommends.</p> <p>The Board of Medicine is requesting to develop a joint task force with the Board of Pharmacy to discuss this process and the requirements to review collaborative practice agreements. The Board should select two members to send to the Joint Task Force.</p>	

0207-O-06	<u>Verbal Report on DC Pharmacy Robberies</u>	Mr. Lawrence Holland
0207-O-07	Request for approval of LGBTQ Cultural Competency Continuing Education (a) "LGBT Diversity in the Workplace: Your Responsibilities" (Course Handout) (b) "Section: HIV/AIDS Update for Healthcare Professionals, LGBTQ Cultural Competency" (Course Handout)	
<u>Public Comments</u>		
Motion to Adjourn the Open Session	"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __: __